TransCode Therapeutics Reports Initial Dosing In Fourth Cohort Of Phase 1 Clinical Trial With TTX-MC138
Benzinga Newsdesk 1 year ago
BiotechNewsGeneral
First patient in Cohort four has been treated with TTX-MC138Ten patients have been treated with TTX-MC138 at escalating dose levelsAdditional patients being evaluated for eligibility for expanded enrollmentNo significant
- First patient in Cohort four has been treated with TTX-MC138
- Ten patients have been treated with TTX-MC138 at escalating dose levels
- Additional patients being evaluated for eligibility for expanded enrollment
- No significant safety or dose limiting toxicities have been reported